Abstract: A coupling assembly and method for retrofitting a water pipe for installation of a pipe insert or device is disclosed. The coupling assembly may include a plunger assembly, a two-part clam shell, an adapter port, and an internally ribbed flexible sleeve including first internal ribs and second internal ribs, wherein the first internal ribs are configured to engage a grooved portion of the adapter port. Prior to installation, a first portion of the internally ribbed flexible sleeve may be attached to the adapter port and a second portion of the sleeve may be rolled up over the first portion. The method may include aligning the port adapter with the cut water pipe; rolling the second portion of the sleeve from the port adapter onto the cut pipe; placing a two-piece clam shell over the sleeve; and tightening two oppositely treaded nuts over the two-piece clam shell.

Abstract: A coupling assembly and method for retrofitting a water pipe for installation of a pipe insert or device is disclosed. The coupling assembly may include a plunger assembly, a two-part clam shell, an adapter port, and an internally ribbed flexible sleeve including first internal ribs and second internal ribs, wherein the first internal ribs are configured to engage a grooved portion of the adapter port. Prior to installation, a first portion of the internally ribbed flexible sleeve may be attached to the adapter port and a second portion of the sleeve may be rolled up over the first portion. The method may include aligning the port adapter with the cut water pipe; rolling the second portion of the sleeve from the port adapter onto the cut pipe; placing a two-piece clam shell over the sleeve; and tightening two oppositely treaded nuts over the two-piece clam shell.

Abstract: The present disclosure is directed to capsules, for example, softgel capsules for oral administration that have on their surface laser etching that penetrates at least partially into the surface of the capsule, reduces the structural integrity of the capsule while preventing exposure of the interior contents to the outside environment, and increases the rate of release of active ingredients contained within.

Abstract: The invention relates to compound of formula (I): A-X1-L-X2-B??(I) and salts, solvates and tautomers thereof, which are useful as medicaments, in particular as anti-proliferative agents and for use as a drug in an antibody-drug conjugate; wherein A is a group selected from: X1 and X2 are independently selected from O, S, NR28, CR28R29, CR28R29O, C(?O), C(?O)NR28, NR28C(?O), C(O)—RA—C(O)—NH, C(O)—RA—NH—C(O), C(O)—NH—RA—C(O), NH—C(O)—RA—C(O), NH—C(O)—RA—C(O)—NH, NH—C(O)—RA—NH—C(O), C(O)—NH—RA—NH—C(O), C(O)—NH—RA—C(O)—NH, O—C(O) and C(O)—O or is absent; L is selected from an amino acid, a peptide chain having from 2 to 12 amino acids, a paraformaldehyde chain —(OCH2)1-24—, a polyethylene glycol chain —(OCH2CH2)1-12— and —(CH2)m—Y6—(CH2)n— wherein Y6 is selected from —(CH2)z— and a group (L1) a group (L1) that is selected from arylene, monocyclic heteroarylene, monocyclic cycloalkylene, monocyclic cycloalkenylene and monocyclic heterocyclylene groups optionally substituted with up to three optional subst

Abstract: The present invention provides a compound of formula (I): (T-X4)p-B1-X3-A-X2-L-X1-AM or pharmaceutically acceptable salts, tautomers, stereoisomers or mixtures thereof; wherein AM is (AM1); (AM2); or (AM3); with the proviso that the compound of formula (I) contains at least one sigma hole group; and with the proviso that no more than one of A, B1 and T is a sigma hole group; and each sigma hole group is independently: (SH1); (SH2); (SH3); (SH4); (SH5); (SH6); (SH7); (SH8); (SH9); or (SH10).

Abstract: The invention relates to a compound of formula (I): or salts, solvates, isomers or tautomers thereof, wherein; A is a group selected from: R1 is selected from H and halogen; either R2 is selected from —CH2-halogen, C1-6 alkyl and H, and R3 is H or is absent; or R2 and R3 together with the carbon atoms to which they are attached form a cyclopropyl ring; SP is a spacer group; B is a polycyclic group: R11, R12, R13 and R14 are selected such that either: (aa) one of R11, R12, R13 and R14 is E and another of R11, R12, R13 and R14 is an optionally substituted Ar1 group; or (ab) one of R11, R12, R13 and R14 is Rx, wherein Rx is Ar1—Z1-E or -E1-Z1—Ar1; and Ar1 is an optionally substituted C5-20 aryl or C5-10 heteroaryl group each E is independently selected from (CH2)j—S(0)2—NR25R26, (CH2)j—S(0)2-0H, CH2CH2[0CH2CH2]WR25 and E1; and Z1 is NR26, C(=0)-0, O or is absent and these compounds are useful as medicaments, in particular as anti-proliferative agents.

Abstract: A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M? are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.

Abstract: A compound of formula (I) and salts and solvates thereof, wherein: R10 is a nitrogen protecting group and R11 is either OH or O—R12, wherein R12 is an oxygen protecting group, or R10 and R11 together form a double bond between N10 and C11; and R10? and R11? are selected from the same options as R10 and R11 respectively.

Abstract: The invention provides systematic methods for identification of candidate compounds useful in treatment of conditions initiated or modulated by genetic expression. The methods of the invention permit efficient identification of candidates suitable for verification testing by in vitro and/or in vivo models.

Abstract: Disclosed are compounds of Formula (I) wherein X, Y, Ri-R7,T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula (I); a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula (I); a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula (I); and a method of preparing a compound of Formula (I) as described herein.

Abstract: A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M? are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.

Abstract: A compound of the formula II: wherein: R?2 is CHR?2, where R?2 is H. R6 and R9 are H and R7 is OMe and the compound is a dimer with each monomer being the same and being of formula II, where the R8 groups of the monomers form together a bridge having the formula —O—(CH2)p—O—, where p is 5, linking the monomers.

Abstract: Compounds of formula (I): formula (I) and salts, solvates, chemically protected forms, and prodrugs thereof, are C disclosed wherein R2 is selected from: an optionally substituted napthyl group; an optionally substituted thiophenyl or furanyl group; and a phenyl group substituted by: one or more chloro or fluoro groups; an ethyl or propyl group; a 4-t-butyl group; a 2-methyl group; or two methyl groups in the 2- and 6- positions.